Enterprise Value
-63.51M
Cash
130M
Avg Qtr Burn
-14.89M
Short % of Float
0.11%
Insider Ownership
3.68%
Institutional Own.
47.71%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTP-300 +/- Nivolumab Details Chronic hepatitis B | Phase 2b Update | |
VTP-300 + AB-729 Details Chronic hepatitis B | Phase 2a Update | |
VTP-850 Details Human papillomavirus, Prostate cancer, Cancer | Phase 1/2 Data readout | |
VTP-600 Details Non-small cell lung carcinoma | Phase 1/2 Data readout | |
VTP-200 Details Human papillomavirus | Phase 1/2 Update | |
VTP-1000 Details Celiac disease | Phase 1 Initiation |